BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1212 related articles for article (PubMed ID: 33579599)

  • 1. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
    Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
    Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
    Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
    J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
    Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
    Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
    Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
    J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
    Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
    Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
    Yang F; Li X; Zhang L; Cheng L; Li X
    J Pharmacol Sci; 2018 Jun; 137(2):116-121. PubMed ID: 29960845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
    Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
    J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
    Colbert LE; Petrova AV; Fisher SB; Pantazides BG; Madden MZ; Hardy CW; Warren MD; Pan Y; Nagaraju GP; Liu EA; Saka B; Hall WA; Shelton JW; Gandhi K; Pauly R; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS
    Cancer Res; 2014 May; 74(10):2677-87. PubMed ID: 24626090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
    Okada Y; Takahashi N; Takayama T; Goel A
    Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.
    Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y
    Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.